MedPath

Effect of Starter Formula on Infection Prevention

Not Applicable
Completed
Conditions
Gastro-intestinal Infections
Infections With Fever
Interventions
Other: starter infant formula with pro and prebiotics
Other: Placebo comparator
Registration Number
NCT01880970
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

The aim of this trial is to test the efficacy of an infant formula containing synbiotics on the prevention of gastro-intestinal infections.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
477
Inclusion Criteria
  • Healthy newborn infant
  • Full term infant (≥ 37 weeks gestation; ≤ 42 weeks gestation)
  • Age of infant is ≤ 13 days at the time of enrollment
  • Birth weight ≥ 2500g and ≤ 4500g
  • For the FF groups: The infant's mother has elected not to breastfeed
  • For the BF group: The infant's mother has elected to fully breastfeed her baby, from enrollment to at least 3 months of age
  • Having obtained his/her legal representative's informed consent
Exclusion Criteria
  • Congenital illness or malformation that may affect normal growth (especially immunodeficiencies)
  • Significant pre-natal and/or post-natal diseases
  • Perinatal antibiotic or infants on antibiotics at the time of inclusion
  • Infants whose mother has had an acute infection during the last month of pregnancy
  • Re-hospitalisation for more than 2 days in the first 14 days of life (exceptionally, infants re-hospitalized because of jaundice may be enrolled in the study)
  • Receiving infant formula containing probiotics and/or prebiotics at the time of enrollment
  • Newborn whose parents / caregivers cannot be expected to comply with treatment
  • Newborn currently participating in another interventional clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Starter infant formula with pro and prebioticsstarter infant formula with pro and prebioticsstarter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
starter infant formula without pro and prebioticsPlacebo comparatorstarter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
Primary Outcome Measures
NameTimeMethod
Diarrhea and all infections with feverover 6 months and 1 year

Mean event rate of diarrhea and all infections with fever per child over 6 months and 1 year

Secondary Outcome Measures
NameTimeMethod
Morbidityover 6 months and 1 year

Frequency of episodes of morbidity (adverse events), especially mean event rate of respiratory illnesses per child over 6 months and 1 year

Anthropometryuntil 1 year

Anthropometry (weight (kg), length (cm), head circumference (cm) and skin fold)

Digestive toleranceuntil 1 year

Digestive tolerance (stool characteristics and frequency, vomiting, regurgitation, frequency of colic)

Stool characteristicsat 3 and 6 months

* Stool bacterial populations (Bifidobacteria, Lactobacilli Species, Clostridium, Bacteroides, Staphylococci epidermitis, presence or absence of B. lactis)

* Stool pH

* Stool and saliva S.IgA

* Stool Alpha 1-antitrypsine as infection/inflammation marker

Trial Locations

Locations (7)

Vrije Universiteit Medisch Centrum, Afdeling Kindergeneeskunde

🇳🇱

Amsterdam, Netherlands

Hôpital Arnaud de Villeneuve, Service de pédiatrie 2

🇫🇷

Montpellier, France

Hôpital de la Croix Rousse, Service de réanimation néonatale

🇫🇷

Lyon, France

Maternité régionale de Nancy, Service de Néonatologie

🇫🇷

Nancy, France

Universitätsklinikum Gießen und Marburg, Zentrum für Kinderheilkunde und Jugendmedizin

🇩🇪

Giessen, Germany

Charité Campus Virchow-Klinikum, Klinik für Geburtsmedizin

🇩🇪

Berlin, Germany

Klinikum Ernest von Bergmann, Klinik für Kinder- und Jugendmedizin

🇩🇪

Potsdam, Germany

© Copyright 2025. All Rights Reserved by MedPath